In his weekly clinical update Dr. Griffin discusses the annual economic burden of respiratory syncytial virus in adults in the US, recombinant or standard-dose influenza vaccine in adults under 65 years of age, maternal vaccine effectiveness against influenza-associated hospitalizations and emergency department visits in iInfants, influenza positive tests reported to CDC by US clinical laboratories, update on COVID-19, risk of severe maternal morbidity associated with SARS-CoV-2 infection during pregnancy, COVID-19 rapid antigen tests with self-collected vs health care worker–collected nasal and throat swab specimens, optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation, long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study, and risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode RSV economic burden, US (J Inf Dis) Recombinant or standard dose influenza vaccine (NEJM) Maternal vaccine effectiveness against influenza in Infants (JAMA Ped) Weekly influenza surveillance report (MMWR) COVID data tracker (hospital admissions, national trend) Risk of severe maternal morbidity associated with SARS-CoV-2 infection (J Inf Dis) COVID-19 rapid antigen tests with nasal and throat swab specimens (JAMA Net Open) Optimal timing of nirmatrelvir/ritonavir (Nat Comm) Long-term outcomes following hospital admission for COVID-19 vs influenza (Lancet) Contribute to our MicrobeTV fundraiser at PWB Letters read on TWiV 1072 Dr. Griffin’s COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]